FIELD: biotechnology.
SUBSTANCE: invention relates to a humanized antibody, which binds to the C3 epitope of the human complement component. DNA encoding the mentioned antibody, an expression vector, for expressing the mentioned antibody, and also a ovarian cells' strain of chinese hamster which produces the mentioned antibody are also disclosed.
EFFECT: invention has the ability to bind specifically to the C3 epitope of the human complement component, which allows the effective treatment of diseases associated with the C3 component of the human complement.
12 cl, 6 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODY TO THE CONFORMATIONAL EPITOPE OF THE HUMAN COMPLEMENT COMPONENT C3 | 2018 |
|
RU2687609C1 |
| MONOCLONAL ANTIBODY SS3-4 TO CONFORMATION HUMAN EPITOPE C3, STRAIN OF HYBRID MOUSE DNA RKKK(P)764D - PRODUCER OF MONOCLONAL ANTIBODY SS3-4 | 2015 |
|
RU2584582C1 |
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2013 |
|
RU2551235C2 |
| HUMANIZED ANTIBODY 6H8HU, BINDING TO TUMOUR ANTIGEN PRAME, DNA FRAGMENTS CODING SAID ANTIBODY AND ANTIGEN-BINDING ANTIBODY FRAGMENT | 2020 |
|
RU2768737C1 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
| ANTIBODIES AGAINST FACTOR D AND THEIR USE | 2018 |
|
RU2799044C2 |
| HUMANIZED TAU-ANTIBODY | 2013 |
|
RU2644242C2 |
| HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
| HUMANIZED ANTIBODIES TO CTLA4 | 2012 |
|
RU2629768C2 |
